Education
About Us
Working with TipRanks
Follow Us
Acurx Pharmaceuticals (ACXP)
NASDAQ:ACXP
Total Valuation
Acurx Pharmaceuticals has a market cap or net worth of $7.32M. The enterprise value is $6.10M.
Market Cap$7.32M
Enterprise Value$6.10M
Share Statistics
Acurx Pharmaceuticals has 1,584,775 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding1,584,775
Owned by Insiders8.10%
Owned by Institutions0.37%
Financial Efficiency
Acurx Pharmaceuticals’s return on equity (ROE) is -22.93 and return on invested capital (ROIC) is -2292.74%.
Return on Equity (ROE)-22.93
Return on Assets (ROA)-3.66
Return on Invested Capital (ROIC)-2292.74%
Return on Capital Employed (ROCE)-22.93
Revenue Per Employee0.00
Profits Per Employee-3.53M
Employee Count4
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Acurx Pharmaceuticals is ―. Acurx Pharmaceuticals’s PEG ratio is ―.
PE Ratio―
PS Ratio―
PB Ratio―
Price to Fair Value22.54
Price to FCF―
Price to Operating Cash Flow-0.66
PEG Ratio―
Income Statement
In the last 12 months, Acurx Pharmaceuticals had revenue of 0.00 and earned -14.10M in profits. Earnings per share was -17.59.
Revenue0.00
Gross Profit0.00
Operating Income-14.10M
Pretax Income-14.10M
Net Income-14.10M
EBITDA-14.10M
Earnings Per Share (EPS)-17.59
Cash Flow
In the last 12 months, operating cash flow was -8.16M and capital expenditures 0.00, giving a free cash flow of -8.16M billion.
Operating Cash Flow-8.16M
Free Cash Flow-8.16M
Free Cash Flow per Share-5.15
Dividends & Yields
Acurx Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.38
52-Week Price Change-89.00%
50-Day Moving Average7.48
200-Day Moving Average11.95
Relative Strength Index (RSI)36.06
Average Volume (3m)77.34K
Important Dates
Acurx Pharmaceuticals upcoming earnings date is Nov 18, 2025, After Close (Confirmed).
Last Earnings DateAug 12, 2025
Next Earnings DateNov 18, 2025
Ex-Dividend Date―
Financial Position
Acurx Pharmaceuticals as a current ratio of 1.19, with Debt / Equity ratio of 0.00%
Current Ratio1.19
Quick Ratio1.19
Debt to Market Cap0.00
Net Debt to EBITDA0.26
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Acurx Pharmaceuticals has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Acurx Pharmaceuticals EV to EBITDA ratio is -0.72, with an EV/FCF ratio of -0.98.
EV to Sales0.00
EV to EBITDA-0.72
EV to Free Cash Flow-0.98
EV to Operating Cash Flow-0.98
Balance Sheet
Acurx Pharmaceuticals has $6.06M in cash and marketable securities with $0.00 in debt, giving a net cash position of -$6.06M billion.
Cash & Marketable Securities$6.06M
Total Debt$0.00
Net Cash-$6.06M
Net Cash Per Share-$3.83
Tangible Book Value Per Share$0.72
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Acurx Pharmaceuticals is $30.50, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$30.50
Price Target Upside560.17% Upside
Analyst ConsensusModerate Buy
Analyst Count2
Revenue Growth Forecast―
EPS Growth Forecast53.79%